Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Biocon's Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate to Severe COVID-19 Patients

Posted On: 2020-07-11 03:34:13


Biocon Ltd. (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced today that it has received the Drugs Controller General of India's (DCGI) approval to market Itolizumab (ALZUMAb™) Injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19.

Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications. Biocon has repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody launched in India in 2013 as ALZUMAb™ for treating chronic plaque psoriasis, for the treatment of CRS in moderate to severe ARDS patients due to COVID-19.

Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park, Bengaluru.

The SARS-CoV-2 virus has been observed to induce an overreaction of the immune system, generating a large number of cytokines that can cause severe damage to the lungs and other organs, and, in the worst scenario, multi-organ failure and even death.

The approval of Itolizumab, from the DCGI is based on the results from the successful conclusion of a randomized, controlled clinical trial at multiple hospitals in Mumbai and New Delhi. The study focussed on the safety and efficacy of Itolizumab in preventing CRS in moderate to severe ARDS patients due to COVID-19. The primary endpoints for reduction in mortality rate were met and other key secondary endpoints for efficacy and biomarkers were also achieved.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said: "As an innovation-led biopharmaceuticals company, I am proud of the successful outcome of the pivotal study we conducted with our novel immuno-modulating anti-CD6 monoclonal antibody, Itolizumab, which has proven to be an efficacious intervention in treating the serious hyper immune response seen with COVID-19. The data is compelling and I am confident that this 'first-in-class' biologic will save lives and help reduce the mortality rate in our country.

"This positions India amongst the leading global innovators in their effort to overcome the COVID-19 pandemic. The randomized control trial indicated that all the patients treated with Itolizumab (ALZUMAb™) responded positively and recovered. The control arm that did not receive Itolizumab unfortunately had deaths. Itolizumab is now approved for the treatment of CRS in patients with moderate to severe ARDS due to COVID-19. We plan to take this therapy to other parts of the world impacted by the pandemic.

"Itolizumab's unique mechanism of action made it an ideal candidate for treating the 'cytokine storm', which is a leading cause of death in COVID-19 patients. I am pleased that our R&D and clinical teams delivered on this promising hypothesis in such a short period of time. It is a proud moment for all of us at Biocon and we would like more and more patients to benefit from this therapy. I also thank the investigators and the regulators for the sense of urgency that they displayed in this study.

"ALZUMAb™ has a seven-year proven track record of safety as doctors in India have been prescribing this biologic to treat acute psoriasis and ensure a better quality of life for patients and now we will be able to save many critically ill COVID 19 patients with our drug."

Dr Suresh Kumar, Medical Director, Lok Nayak Hospital, Delhi said: "At the time of this COVID-19 pandemic, we do not have any specific treatment for patients who are losing the fight against the disease in spite of best supportive care. Lok Nayak Hospital was one of the sites of the Itolizumab study wherein we used Itolizumab to treat eight patients. These patients did extremely well even with a single dose of Itolizumab. Patients who were with initial oxygen saturation of less than 80% and would have been put on ventilator support with little chance of survival, recovered completely when treated with Itolizumab and got discharged. I sincerely believe Itolizumab will not only help in reducing morbidity and mortality of COVID-19 patients but will also help us in judiciously managing healthcare resources like ICUs and ventilators for critically ill patients."

Dr Mohan Joshi, Dean, BYL Nair Hospital, Mumbai, said: "In our hospital, we have tried Itolizumab in many COVID-19 patients with moderate to severe ARDS and found significant improvement in clinical, radiological and inflammatory markers after administering Itolizumab. These outcomes were quite evident with one dose of Itolizumab when administered before the 'cytokine storm' set in. Most of the patients have well tolerated the drug. Given the growing surge of COVID-19 cases, I would recommend use of Itolizumab in moderate to severe complications in COVID-19."

Dr Sandeep Athalye, Chief Medical Officer, Biocon Biologics, said: "We are delighted with the results of the clinical trial for Itolizumab in India. Itolizumab demonstrated statistically significant advantage over the control arm, in one month mortality rate. Key efficacy parameters such as IL-6, TNF-a, PaO2 and SpO2 (oxygen saturation) improvement without increasing FiO2 (oxygen flow) also showed statistically significant advantage for Itolizumab arm over the control arm. All the patients on Itolizumab arm were weaned off oxygen by Day 30, and none needed ventilator support unlike the control arm. Key secondary endpoints of clinical markers of inflammation such as serum ferritin, d-dimer, LDH and CRP showed clinically significant suppression post dose and correlated well with clinical improvement in symptoms and chest x-ray images. Itolizumab was overall well tolerated and was found to be safe. Itolizumab when administered to patients with moderate to severe ARDS due to COVID19, prevents morbidity and mortality due to cytokine storm.

India currently has more than 283,400* documented active coronavirus infections and over 22,100* deaths.

Itolizumab's unique mechanism of action of immunomodulation involves binding to the CD6 receptor and blocking the activation of T lymphocytes, which in turn suppresses the pro-inflammatory cytokines, thus reducing the cytokine storm and deadly inflammatory response.

Biocon launched ALZUMAb™ (Itolizumab) in India in 2013 for the treatment of chronic plaque psoriasis. Many patients have benefitted from this novel therapy.

Shares of BIOCON LTD. was last trading in BSE at Rs.414.3 as compared to the previous close of Rs. 406.1. The total number of shares traded during the day was 519987 in over 9032 trades.

The stock hit an intraday high of Rs. 420.35 and intraday low of 400.45. The net turnover during the day was Rs. 215773012.

*Source: Ministry of Health & Family Welfare, Govt of India (Update as of 11 July 2020, 08:00 IST)


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Sinclairs Hotels Ltd Q1 PAT at Rs. 0.48 crore

National Fittings Ltd Q1 loss at Rs. 0.68 crore

NESCO Ltd posts consolidated PAT of Rs. 51.32 crore in Q1FY21

MRF Ltd Q1FY21 consolidated net profit plunges to Rs. 13.46 crore

NIRLON Ltd reports Rs. 32.47 crore PAT in Q1

Valiant Communications Ltd Q1 consolidated net loss at Rs. 0.44 crore

Punjab Alkalies and Chemicals Ltd Q1 loss widens to Rs. 3.32 crore

The Ramco Cements Ltd Q1FY21 consolidated PAT at Rs. 117.25 crore

XPRO India Ltd Q1 consolidated loss at Rs. 12.70 crore

Infosys to accelerate Digital Skills and Innovation across Australia and New Zealand via its GovHack 2020 partnership

Wonderla Holidays Ltd. launches 2nd Wonder Kitchen Outlet at Rajarajeshwari Nagar, Bangalore

Parag Milk Food Ltd. introduces a new product to its premium category by launching Pride of Cows Curd

Mindteck Reports Financial Results for Q1 2020-21

Steel Strips Wheels Ltd promoter group release 44132 shares from pledge

Shriram Transport Finance Company Ltd announces Q1FY21 results

The Tata Power Company Ltd allots 49,05,66,037 Equity Shares to Tata Sons

Hero MotoCorp announces Q1FY21 results

Trent Ltd announces Q1 FY21 results

Minda Corporation Ltd Q1 consolidated loss at Rs. 35.40 crore

TATA Steel Ltd Q1 consolidated loss at Rs. 4648.13 crore

TIMKEN India Ltd Q1 PAT slumps to Rs. 3.15 crore

Mindteck India Ltd Q1FY21 consolidated net profit at Rs. 1.67 crore

TNPL reports earnings for Q1FY21

Balkrishna Industries Ltd board declares interim dividend of Rs. 3 for FY21

CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France

JSPL becomes first company to supply Head Hardened rails to Metro Rail projects in India

Paisalo Digital Ltd reports Rs. 15.06 crore consolidated PAT in Q1FY21

Hindustan Tin Works Ltd Q1 PAT at Rs. 0.79 crore

Shivalik Rasayan Ltd Q1 consolidated PAT lower at Rs. 2.50 crore

Rossell India Ltd Q1FY21 PAT soars to Rs. 9.12 crore

Shriram Transport Finance Company Ltd Q1FY21 consolidated net profit climbs QoQ to Rs. 319.25 crore

Excel Industries Ltd Q1FY21 consolidated PAT declines to Rs. 8.21 crore

Amines & Plasticizers Ltd Q1 consolidated PAT rises to Rs. 7.61 crore

Ishita Drugs & Industries Ltd posts PAT of Rs. 0.09 crore in Q1

PG Electroplast Ltd Q1FY21 loss widens to Rs. 8.48 crore

Orient Bell Ltd Q1 consolidated loss at Rs. 11.42 crore

Hercules Hoists Q1FY21 profit plunges to Rs. 0.24 crore

I G Petrochemicals posts consolidated PAT of Rs. 2.22 crore in Q1FY21

Endurance Technologies Ltd Q1FY21 consolidated loss at Rs. 24.90 crore

Balkrishna Industries Ltd Q1 consolidated PAT slides to Rs. 131.56 crore

BPCL Q1FY21 consolidated net profit at Rs. 2035.39 crore

AGC Networks completes the acquisition of Pyrios

Eicher Motors Limited announces financial results for the quarter ended June 30, 2020

TCS a Leader and Star Performer in Healthcare Provider Digital Services: Everest Group

GAIL reports Turnover of Rs. 12,060 crore, PAT of Rs. 256 crore in Ql FY21

Ahluwalia Contracts secures new order of Rs. 290 crore

Wipro Limited recognized as the winner of Data Estate Modernization 2020 Microsoft Partner of the Year

SKM Egg Products Export India Ltd board recommends final dividend of Rs. 0.50 for FY20

L&T Construction bags significant contracts from prestigious clients

Shoppers Stop Reported Revenue of Rs.60.7 Crs and EBITDA Loss of Rs. 132.8 Crs in Q1FY21







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019